GlassScriptPhysician profile
Debra R Mcclain
NPI 1487657896
$20,526.64
in general payments reported to CMS, 2019-2025
57 companies · $2,792 in 2025
The $2,792 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,917 · 2020: $2,015 · 2021: $3,332 · 2022: $3,188 · 2023: $3,109 · 2024: $3,174 · 2025: $2,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,995 · Education: $79.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,994.90 |
| Education | $79.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,430.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,365.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,362.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,191.45 | 2019-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,101.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,100.04 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $902.70 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Teva Pharmaceuticals USA, INC. | $805.33 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $741.63 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $709.35 | 2019-2025 | Spravato, Xarelto |
| Sanofi-Aventis U.S. LLC | $698.53 | 2019-2023 | |
| Grifols USA, LLC | $537.13 | 2019-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $487.05 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $483.09 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $423.43 | 2022-2025 | Caplyta |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.